About Us: Board of Directors
EMPOWERING A BOLD VISION
Our board members empower our culture, diversity and advancement as global leaders in a regenerative medicine company. Collectively, our advisors provide innovative solutions and industry-leading guidance to focus on patient care and medical successes made possible from their direction and insistence that only results change the way exceptional care is administered.
Mr. Panaccio was appointed as AVITA Medical Chairman of the Board in July 2014 with more than 30 years of executive leadership skills in healthcare and life sciences experience, including developing company concepts through finished commercialization.
Mr. Panaccio is positioned on additional Boards including Non-Executive Director of ASX50 company, one of the world’s largest medical diagnostics companies; Sonic Healthcare Limited since 2005; Non-Executive Director Unison Housing Limited; Non-Executive Chairman of Genera Biosystems Limited; and Non-Executive Director Rhythm Biosciences Limited. Mr. Panaccio’s past executive and board roles includ Melbourne Pathology Group, Monash IVF Group, Health Networks Australia Group and Primelife Corporation Limited.
Jeremy Curnock Cook
Jeremy is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years. Founder and Managing Director of BioScience Managers, Jeremy brings his decades of international experience to our investment team, to support the identification of investment opportunities and in the strategic assessment of value creation options, in particular through M&A and expansion into new geographies. He actively supports portfolio companies through his executive and non-executive roles.
Over his career, Jeremy has successfully managed in excess of US$1billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and significant investor in the sector. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. He co-created a European-focused seed fund with Johnson & Johnson and built the International Biotechnology Trust. He has served on more than 40 boards of directors in the life science sector, in the UK, Europe, USA, Canada, Japan and Australia. Jeremy currently serves on the following boards: AVITA Medical Ltd appointed October 2012, Sea Dragon appointed October 2012, Rex Bionics Pty Ltd appointed February 2012, Armata Pharmaceuticals July 1995, SummatiX Pty Ltd appointed July 2017, Adherium Ltd appointed April 2015, JLCC Ltd appointed December 2019, Bioscience Managers UK Ltd appointed August 2017, Bioscience Managers Pty Ltd appointed January 2003, International BioScience Managers Ltd appointed March 2000, Arecor Ltd appointed October 2018, Smart Matrix Ltd appointed February 2013, and Gen InCode appointed July 2020.
Dr. Michael Perry
Chief Executive Officer & Executive Director
Appointed to the Board in February 2013, and as CEO in June 2017. Dr. Perry brings extensive experience across the global pharmaceutical/medical device value chain, including expertise in cell and cell-based gene therapies. He has been materially involved in the successful development and launch of over 30 prescription products, 14 of which achieved blockbuster status. He has held numerous past positions in the industry including Chief Scientific Officer of Novartis’ Cell & Gene Therapy Business Unit, Senior VP of business development and licensing for Novartis AG, Global Head of R&D for Baxter, and others. He is an independent Director on the board of Arrowhead Pharmaceuticals.
Mr. Drapeau was appointed to the AVITA Medical Board in January 2016.
Mr. Drapeau’s current positions include Independent Director at AmphliPhi Biosciences Corporation (NYSE) and Independent Director at Surface Pharmaceuticals Inc; His previous senior positions included roles with InSite Vision Inc as CFO and Vice President; Independent Director at Bio-Rad Laboratories, Inc. (NYSE). Nektar Therapeutics as Senior Vice President and CFO, BioMarin Pharmaceutical, Inc. as Senior Vice President and CFO; Audit Partner at Arthur Andersen, LLP; Independent Director at InterMune, Inc. (NASDAQ); Bionovo, Inc. (NASDAQ); and Inflazyme Pharmaceuticals LTD (TSE).
Mr. Drapeau has a bachelor of science in Mechanical Engineering and an MBA, both from Stanford University.
Professor Suzanne Crowe
Professor Suzanne Crowe AO, has served as a Non-Executive Director of AVITA Medical since January 2016. Australian-based, she is a physician-scientist and ASX/Nasdaq-listed company director with expertise in supporting companies with their medical and scientific strategies. A Fellow of the Australian Institute of Company Directors, she is currently a Non-Executive Director of St Vincent’s Health Australia Ltd, the country’s largest not-for-profit health and aged care provider, and Non-Executive Director of Sonic Healthcare Ltd, a large global medical diagnostic company. She was appointed Emeritus Professor, Monash University, Melbourne in 2020. After 35 years at both, she has recently retired from the Burnet Institute, having served as Associate Director Clinical Research, and the university-affiliated Alfred Hospital Melbourne, where she held the appointment of Senior Specialist Physician in Infectious Diseases. She was appointed as Officer of the Order of Australia in June 2020 in recognition of her distinguished services to health, clinical governance, biomedical research and education.